Perspective Therapeutics (CATX) Non Operating Interest Expenses (2023 - 2026)

Perspective Therapeutics (CATX) has 4 years of Non Operating Interest Expenses data on file, last reported at $105000.0 in Q1 2026.

• For the quarter ending Q1 2026, Non Operating Interest Expenses fell 17.97% year-over-year to $105000.0; the trailing twelve-month figure through Mar 2026 stood at $229000.0 (up 55.78% YoY), and the FY2025 full-year result was $376000.0, up 683.33% from the prior year.
• Non Operating Interest Expenses fell to $105000.0 in Q1 2026, from $128000.0 in the prior quarter.
• In the past five years, Non Operating Interest Expenses ranged from a high of $128000.0 in Q1 2025 to a low of -$73000.0 in Q4 2024.
• A 4-year average of $37666.7 and a median of $26000.0 in 2023 frame the typical range for Non Operating Interest Expenses.
• Across the five-year window, Non Operating Interest Expenses surged 392.86% in 2024 and decreased 17.97% in 2026, its largest moves.
• Tracing CATX's Non Operating Interest Expenses over 4 years: stood at $14000.0 in 2023, then plunged by 621.43% to -$73000.0 in 2024, then surged by 275.34% to $128000.0 in 2025, then declined by 17.97% to $105000.0 in 2026.
• Business Quant data shows CATX's Non Operating Interest Expenses at $105000.0 in Q1 2026, $128000.0 in Q1 2025, and -$73000.0 in Q4 2024.